Does using a higher cutoff for the percentage of positive cells improve the specificity of HER-2 immunohistochemical analysis in breast carcinoma?

被引:13
作者
Hameed, Omar [1 ]
Chhieng, David C. [1 ]
Adams, Amy L. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Pathol, Div Anat Pathol, Birmingham, AL 35294 USA
关键词
breast carcinoma; HER-2; immunohistochemistry; fluorescence in situ hybridization; FISH; concordance;
D O I
10.1309/L9HQHR0798FH0LQN
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
This study was performed to determine whether using a 30% cutoff for the proportion of HER-2+ cells would increase the specificity of HER-2 immunohistochemical analysis. Blinded to the HER-2 amplification status, 3 pathologists retrospectively reviewed HER-2-stained sections of breast carcinoma and considered cases to be positive for protein overexpression (3+) using 3 cutoff levels, 10%, 30%, and 50%, for the proportion of cells with intense uniform staining. Of 98 cases, 27 (28%) were positive by fluorescence in situ hybridization (FISH), and 32 (33%), 28 (29%), and 26 (27%) were considered positive for overexpression using cutoffs of 10%, 30%, and 50%, respectively. The specificity values of HER-2 immunohistochemical analysis were 82%, 86%, and 87% for the different cutoffs, and the concordance rates of 3+ cases with FISH were 59%, 64%, and 65%, for the cutoffs of 10%, 30%, and 50%, respectively. These findings seem to somehow support the recently proposed American Society of Clinical Oncology/College of American Pathologists guideline recommendations for HER-2 testing; nevertheless further studies are suggested.
引用
收藏
页码:825 / 829
页数:5
相关论文
共 32 条
[1]   Testing for erbB-2 by immunohistochemistry in breast cancer [J].
Allred, DC ;
Swanson, PE .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (02) :171-175
[2]   Current perspectives on HER2 testing:: A review of national testing guidelines [J].
Bilous, M ;
Dowsett, M ;
Hanna, W ;
Isola, J ;
Lebeau, A ;
Moreno, A ;
Penault-Llorca, F ;
Rüschoff, J ;
Tomasic, G ;
de Vijver, MV .
MODERN PATHOLOGY, 2003, 16 (02) :173-182
[3]  
Carlson Robert W, 2006, J Natl Compr Canc Netw, V4 Suppl 3, pS1
[4]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[5]   Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma [J].
Couturier, J ;
Vincent-Salomon, A ;
Nicolas, A ;
Beuzeboc, P ;
Mouret, E ;
Zafrani, B ;
Sastre-Garau, X .
MODERN PATHOLOGY, 2000, 13 (11) :1238-1243
[6]   Updated recommendations for HER2 testing in the UK [J].
Ellis, IO ;
Bartlett, J ;
Dowsett, M ;
Humphreys, S ;
Jasani, B ;
Miller, K ;
Pinder, SE ;
Rhodes, A ;
Walker, R .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (03) :233-237
[7]  
Field AS, 2001, PATHOLOGY, V33, P278
[8]   Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry:: an interlaboratory study assessing the reproducibility of HER-2/NEU testing [J].
Gancberg, D ;
Järvinen, T ;
di Leo, A ;
Rouas, G ;
Cardoso, F ;
Paesmans, M ;
Verhest, A ;
Piccart, MJ ;
Isola, J ;
Larsimont, D .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 74 (02) :113-120
[9]   Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization [J].
Hammock, L ;
Lewis, M ;
Phillips, C ;
Cohen, C .
HUMAN PATHOLOGY, 2003, 34 (10) :1043-1047
[10]   HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma [J].
Hoang, MP ;
Sahin, AA ;
Ordòñez, NG ;
Sneige, N .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2000, 113 (06) :852-859